C-reactive Protein Levels Among Individuals With COVID-19
Triage Strategies Based on C-reactive Protein Levels Among Individuals With COVID-19: A Prospective Cohort Study
1 other identifier
observational
1,006
1 country
1
Brief Summary
The primary objective of this multi-center study is to clarify the value of a CRP measurement for triage of patients initially presenting with light symptoms of the COVID-19 infection. Current recommendations of management of COVID-19 include large-scale tests for virus. Such tests reveal whether an individual is infected with the virus, however, the demonstration of virus per se has no prognostic value for the ensuing course of the COVID-19 disease. Publications of possible treatments strategies increase exponentially, while evidence of triage of the affected individuals is mainly based on the level of pulmonary affection as measured by the Oxygen saturation. To inform decision making for which patients are to be hospitalized due to risk of developing more severe affection, this study addresses the question, whether triage may be performed with the aid of a simple CRP measurement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 1, 2020
CompletedFirst Posted
Study publicly available on registry
May 4, 2020
CompletedStudy Start
First participant enrolled
May 4, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2021
CompletedAugust 18, 2021
August 1, 2021
4 months
May 1, 2020
August 17, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Hospitalisation
Admission to a hospital. Reason for admission is recorded.
within 28 days
Secondary Outcomes (3)
Death
within 28 days
Transfer to Intensive Care Unit
within 28 days
Oxygen treatment during hospitalisation
within 28 days
Study Arms (1)
Suspected COVID-19
Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.
Interventions
Measurement of CRP value from blood sample taken at covid19 check point (baseline).
Eligibility Criteria
Individuals who are COVID-19 positive at the check point test.
You may qualify if:
- A test for COVID-19 taken at the check point
- Signed, informed consent for blood test to be drawn for the Biobank
You may not qualify if:
- Former admission to hospital for COVID-19
- Direct admission from check point.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Henning Bliddallead
Study Sites (1)
The Parker Institute, Frederiksberg Hospital
Copenhagen, 2000, Denmark
Biospecimen
Blood sample
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Henning Bliddal, DMSc
The Parker Institute
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 1, 2020
First Posted
May 4, 2020
Study Start
May 4, 2020
Primary Completion
August 30, 2020
Study Completion
March 30, 2021
Last Updated
August 18, 2021
Record last verified: 2021-08